AbbVie’s Mavyret: The Hepatitis C Treatment We’ve Been Waiting For?

Cancer treatment: sorting the good news from the hype
August 23, 2017
Multiple sclerosis: Resistance training may reduce brain atrophy
August 23, 2017
Show all

AbbVie’s Mavyret: The Hepatitis C Treatment We’ve Been Waiting For?

Mavyret is the newly approved hepatitis C medications.

The Food and Drug Administration (FDA) recently approved AbbVie’s Mavyret, the newest treatment for chronic hepatitis C virus infection for people without cirrhosis or with compensated cirrhosis. Mavyret (glecaprevir 100 mg and pibrentasvir 40 mg) is taken once daily (three tablets for a total daily dose of glecaprevir 300 mg and pibrentasvir 120 mg) to treat genotypes 1 through 6.

What You Need to Know about Mavyret

AbbVie’s Mavyret is one pill containing two drugs. Both are direct-acting antivirals (DAAs) which means they directly interfere with hepatitis C virus replication. One drug, glecaprevir is an HCV NS3/4A protease inhibitor. The second drug is pibrentasvir, an NS5A inhibitor.

Read full article: AbbVie’s Mavyret: The Hepatitis C Treatment We’ve Been Waiting For? – Hep

Read Full Article: AbbVie’s Mavyret: The Hepatitis C Treatment We’ve Been Waiting For? – Hep

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.